Clinical efficacy of butylphthalide in the treatment of acute cerebral infarction and its effect on serum C-reactive protein / 中国基层医药

ABSTRACT

Objective To observe the clinical efficacy of butylphthalide in the treatment of acute cerebral infarction and its effect on serum C-reactive protein(CRP).Methods A total of 120 inpatients with acute cerebral infarction were randomly assigned into control group (n =60) and observation group (n =60) by the digital table method.The control group was treated with Xueshuantong injection,inhibiting blood platelet and improving brain metabolism.The observation group was treated with butylphthalide based on the treatment of the control group.The changes in serum CRP and clinical efficacy were compared between the two groups 2 weeks after treatment.Results After treatment,the CRP level was decreased greatly in the observation group,but the CRP level was reduced slightly in the control group compared with before treatment,the CRP level in the observation group was (2.54 ± 0.79) mg/L,which was significantly lower than (5.66 ± 1.78) mg/L in the control group (t =12.41,P ＜ 0.05).The total effective rate in the observation group was 75.00％,which was significantly higher than 53.33％ in the control group (x2 =6.13,P ＜ 0.05).The 3-day NIHSS score [(8.62 ± 1.89) points],1-week NIHSS score [(4.21 ± 1.76) points],and 2-week NIHSS score [(5.79 ± 1.36) points] after treatment were significantly lower in the observation group compared with the control group (t =2.84,11.93,6.67,all P ＜ 0.05).Conclusion Based on conventional treatment,butylphthalide injection in the treatment of acute cerebral infarction can remarkably reduce CRP level,alleviate inflammatory reactions,improve cerebral infarction condition and prognosis,exert obvious effect and it is worthy of clinical promotion.